Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David J Good

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Blood|July 24, 2014
Bodies of evidence? Lymphoglandular bodies in aspirate smears of bone marrow involved by aggressive large B-cell lymphomaMichael J Rauh, David J Good
Hematology/Oncology Clinics of North America|July 7, 2009
Atypical lymphoid hyperplasia mimicking lymphomaDavid J Good, Randy D Gascoyne
Hematology/Oncology Clinics of North America|October 29, 2008
Classification of non-Hodgkin's lymphomaDavid J Good, Randy D Gascoyne
Molecular Pharmaceutics|May 10, 2007
Mechanisms by which moisture generates cocrystalsAdivaraha Jayasankar, David J Good, Naír Rodríguez-Hornedo
The American Journal of Dermatopathology|November 7, 2014
Composite mantle cell and primary cutaneous anaplastic large cell lymphoma: case report and review of the literatureCharles Leduc, Ivan I P Blandino, Abdulmohsen Alhejaily, et al.
Molecular Pharmaceutics|November 5, 2015
Mitigation of Adverse Clinical Events of a Narrow Target Therapeutic Index Compound through Modified Release Formulation Design: An in Vitro, in Vivo, in Silico, and Clinical Pharmacokinetic AnalysisDavid J Good, Ruiling Hartley, Neil Mathias, et al.
Pharmaceutical Research|October 23, 2019
Utilization of In Vitro, In Vivo and In Silico Tools to Evaluate the pH-Dependent Absorption of a BCS Class II Compound and Identify a pH-Effect Mitigating StrategyChristoph Gesenberg, Neil R Mathias, Yan Xu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 10, 2013
MicroRNA signature obtained from the comparison of aggressive with indolent non-Hodgkin lymphomas: potential prognostic value in mantle-cell lymphomaRashmi S Goswami, Eshetu G Atenafu, Yali Xuan, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Blood|July 24, 2014
Bodies of evidence? Lymphoglandular bodies in aspirate smears of bone marrow involved by aggressive large B-cell lymphomaMichael J Rauh, David J Good
Hematology/Oncology Clinics of North America|July 7, 2009
Atypical lymphoid hyperplasia mimicking lymphomaDavid J Good, Randy D Gascoyne
Hematology/Oncology Clinics of North America|October 29, 2008
Classification of non-Hodgkin's lymphomaDavid J Good, Randy D Gascoyne
Molecular Pharmaceutics|May 10, 2007
Mechanisms by which moisture generates cocrystalsAdivaraha Jayasankar, David J Good, Naír Rodríguez-Hornedo
The American Journal of Dermatopathology|November 7, 2014
Composite mantle cell and primary cutaneous anaplastic large cell lymphoma: case report and review of the literatureCharles Leduc, Ivan I P Blandino, Abdulmohsen Alhejaily, et al.
Molecular Pharmaceutics|November 5, 2015
Mitigation of Adverse Clinical Events of a Narrow Target Therapeutic Index Compound through Modified Release Formulation Design: An in Vitro, in Vivo, in Silico, and Clinical Pharmacokinetic AnalysisDavid J Good, Ruiling Hartley, Neil Mathias, et al.
Pharmaceutical Research|October 23, 2019
Utilization of In Vitro, In Vivo and In Silico Tools to Evaluate the pH-Dependent Absorption of a BCS Class II Compound and Identify a pH-Effect Mitigating StrategyChristoph Gesenberg, Neil R Mathias, Yan Xu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 10, 2013
MicroRNA signature obtained from the comparison of aggressive with indolent non-Hodgkin lymphomas: potential prognostic value in mantle-cell lymphomaRashmi S Goswami, Eshetu G Atenafu, Yali Xuan, et al.
Pageof 1